Skip to main content
Erschienen in: International Journal of Clinical Oncology 7/2019

27.02.2019 | Original Article

Discrimination between breast invasive ductal carcinomas and benign lesions by optimizing quantitative parameters derived from dynamic contrast-enhanced MRI using a semi-automatic method

verfasst von: Jiawen Yang, Jiandong Yin

Erschienen in: International Journal of Clinical Oncology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

To propose a semi-automatic method for distinguishing invasive ductal carcinomas from benign lesions on breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

Methods

142 cases were included. In the conventional method, the region of interest for a breast lesion was drawn manually and the corresponding mean time–signal intensity curve (TIC) was qualitatively categorized. Only one quantitative parameter was obtained: the maximum slope of increase (MSI). By contrast, the proposed method extracted the suspicious breast lesion semi-automatically. Besides MSI, more quantitative parameters reflecting perfusion information were derived from the mean TIC and lesion region, including the signal intensity slope (SIslope), initial percentage of enhancement, percentage of peak enhancement, early signal enhancement ratio, and second enhancement percentage. The mean TIC was categorized quantitatively according to the value of SIslope. Regression models were established. The diagnostic performance differed between the new and conventional methods according to the Wilcoxon rank-sum test and receiver operating characteristic analysis.

Results

According to the TIC categorization results, the accuracies of the traditional and the new method were 59.16% and 76.05%, respectively (P < 0.05). The accuracy was 63.35% for MSI, which was derived from the manual method. For the semi-automatic method, the accuracies were 81.0% and 78.9% for the lesion region and the corresponding mean TIC regression models, respectively.

Conclusions

The results demonstrate that our proposed semi-automatic method is beneficial for discriminating breast IDCs and benign lesions based on DCE-MRI, and this method should be considered as a supplementary tool for subjective diagnosis by clinical radiologists.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed
2.
Zurück zum Zitat Mayrhofer RM, Ng HP, Putti TC et al (2013) Magnetic resonance in the detection of breast cancers of different histological types. Magn Reson Insights 6(6):33–49PubMedPubMedCentral Mayrhofer RM, Ng HP, Putti TC et al (2013) Magnetic resonance in the detection of breast cancers of different histological types. Magn Reson Insights 6(6):33–49PubMedPubMedCentral
3.
Zurück zum Zitat Weinstein SP, Localio AR, Conant EF et al (2009) Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol 27(36):6124–6128CrossRefPubMedPubMedCentral Weinstein SP, Localio AR, Conant EF et al (2009) Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol 27(36):6124–6128CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Lehman CD, Isaacs C, Schnall MD et al (2007) Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 244(2):381–388CrossRefPubMed Lehman CD, Isaacs C, Schnall MD et al (2007) Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 244(2):381–388CrossRefPubMed
5.
Zurück zum Zitat Kumar A, Srivastava V, Singh S et al (2010) Color Doppler ultrasonography for treatment response prediction and evaluation in breast cancer. Future Oncol 6(8):1265–1278CrossRefPubMed Kumar A, Srivastava V, Singh S et al (2010) Color Doppler ultrasonography for treatment response prediction and evaluation in breast cancer. Future Oncol 6(8):1265–1278CrossRefPubMed
7.
Zurück zum Zitat Brennan M, Spillane A, Houssami N (2009) The role of breast MRI in clinical practice. Aust Fam Physician 38(7):513–519PubMed Brennan M, Spillane A, Houssami N (2009) The role of breast MRI in clinical practice. Aust Fam Physician 38(7):513–519PubMed
8.
9.
Zurück zum Zitat Kim JY, Kim SH, Kim YJ et al (2015) Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers? Magn Reson Imaging 33(1):72–80CrossRefPubMed Kim JY, Kim SH, Kim YJ et al (2015) Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers? Magn Reson Imaging 33(1):72–80CrossRefPubMed
10.
Zurück zum Zitat Li X, Arlinghaus LR, Ayers GD et al (2014) DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med 71(4):1592–1602CrossRefPubMed Li X, Arlinghaus LR, Ayers GD et al (2014) DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med 71(4):1592–1602CrossRefPubMed
11.
Zurück zum Zitat Jansen SA, Lin VC, Giger ML et al (2011) Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol 21(7):1374–1382CrossRefPubMed Jansen SA, Lin VC, Giger ML et al (2011) Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol 21(7):1374–1382CrossRefPubMed
12.
Zurück zum Zitat Abramson RG, Li X, Hoyt TL et al (2013) Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Magn Reson Imaging 31(9):1457–1464CrossRefPubMed Abramson RG, Li X, Hoyt TL et al (2013) Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Magn Reson Imaging 31(9):1457–1464CrossRefPubMed
13.
Zurück zum Zitat Platel B, Mus R, Welte T et al (2014) Automated characterization of breast lesions imaged with an ultrafast DCE-MR protocol. IEEE Trans Med Imaging 33(2):225–232CrossRefPubMed Platel B, Mus R, Welte T et al (2014) Automated characterization of breast lesions imaged with an ultrafast DCE-MR protocol. IEEE Trans Med Imaging 33(2):225–232CrossRefPubMed
14.
Zurück zum Zitat Otsu N (1979) A threshold selection method from gray-level histograms. IEEE T Syst Man CY S 9(1):62–66CrossRef Otsu N (1979) A threshold selection method from gray-level histograms. IEEE T Syst Man CY S 9(1):62–66CrossRef
15.
Zurück zum Zitat Kuhl CK, Mielcareck P, Klaschik S et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211(1):101–110CrossRefPubMed Kuhl CK, Mielcareck P, Klaschik S et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211(1):101–110CrossRefPubMed
16.
Zurück zum Zitat Montemurro F, Martincich L, Sarotto I et al (2007) Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol 17(6):1490–1497CrossRefPubMed Montemurro F, Martincich L, Sarotto I et al (2007) Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol 17(6):1490–1497CrossRefPubMed
17.
Zurück zum Zitat Tozaki M (2013) BI-RADS-MRI terminology and evaluation of intraductal carcinoma and ductal carcinoma in situ. Breast Cancer 20(1):13–20CrossRefPubMed Tozaki M (2013) BI-RADS-MRI terminology and evaluation of intraductal carcinoma and ductal carcinoma in situ. Breast Cancer 20(1):13–20CrossRefPubMed
18.
Zurück zum Zitat Morris EA (2010) Diagnostic breast MR imaging: current status and future directions. Magn Reson Imaging Clin N Am 18(1):57–74CrossRefPubMed Morris EA (2010) Diagnostic breast MR imaging: current status and future directions. Magn Reson Imaging Clin N Am 18(1):57–74CrossRefPubMed
19.
Zurück zum Zitat Lehman CD, Gatsonis C, Kuhl CK et al (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356(13):1295–1303CrossRefPubMed Lehman CD, Gatsonis C, Kuhl CK et al (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356(13):1295–1303CrossRefPubMed
20.
Zurück zum Zitat Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89CrossRefPubMed Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89CrossRefPubMed
21.
Zurück zum Zitat Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46(8):1296–1316CrossRefPubMed Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46(8):1296–1316CrossRefPubMed
22.
Zurück zum Zitat Yabuuchi H, Matsuo Y, Okafuji T et al (2008) Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging 28(5):1157–1165CrossRefPubMed Yabuuchi H, Matsuo Y, Okafuji T et al (2008) Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging 28(5):1157–1165CrossRefPubMed
23.
Zurück zum Zitat Pinker-Domenig K, Bogner W, Gruber S et al (2012) High resolution MRI of the breast at 3 T: which BI-RADSA (R) descriptors are most strongly associated with the diagnosis of breast cancer? Eur Radiol 22(2):322–330CrossRefPubMed Pinker-Domenig K, Bogner W, Gruber S et al (2012) High resolution MRI of the breast at 3 T: which BI-RADSA (R) descriptors are most strongly associated with the diagnosis of breast cancer? Eur Radiol 22(2):322–330CrossRefPubMed
24.
Zurück zum Zitat Renz DM, Böttcher J, Diekmann F et al (2012) Detection and classification of contrast-enhancing masses by a fully automatic computer-assisted diagnosis system for breast MRI. J Magn Reson Imaging 35(5):1077–1088CrossRefPubMed Renz DM, Böttcher J, Diekmann F et al (2012) Detection and classification of contrast-enhancing masses by a fully automatic computer-assisted diagnosis system for breast MRI. J Magn Reson Imaging 35(5):1077–1088CrossRefPubMed
25.
Zurück zum Zitat Levman JE, Causer P, Warner E et al (2009) Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI. Acad Radiol 16(9):1064–1069CrossRefPubMedPubMedCentral Levman JE, Causer P, Warner E et al (2009) Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI. Acad Radiol 16(9):1064–1069CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Agliozzo S, De Luca M, Bracco C et al (2012) Computer-aided diagnosis for dynamic contrast-enhanced breast MRI of mass-like lesions using a multiparametric model combining a selection of morphological, kinetic, and spatiotemporal features. Med Phys 39(4):1704–1715CrossRefPubMed Agliozzo S, De Luca M, Bracco C et al (2012) Computer-aided diagnosis for dynamic contrast-enhanced breast MRI of mass-like lesions using a multiparametric model combining a selection of morphological, kinetic, and spatiotemporal features. Med Phys 39(4):1704–1715CrossRefPubMed
28.
Zurück zum Zitat Chang YC, Huang YH, Huang CS et al (2012) Classification of breast mass lesions using model-based analysis of the characteristic kinetic curve derived from fuzzy c-means clustering. Magn Reson Imaging 30(3):312–322CrossRefPubMed Chang YC, Huang YH, Huang CS et al (2012) Classification of breast mass lesions using model-based analysis of the characteristic kinetic curve derived from fuzzy c-means clustering. Magn Reson Imaging 30(3):312–322CrossRefPubMed
29.
Zurück zum Zitat Levman JE, Martel AL (2011) A margin sharpness measurement for the diagnosis of breast cancer from magnetic resonance imaging examinations. Acad Radiol 18(12):1577–1581CrossRefPubMed Levman JE, Martel AL (2011) A margin sharpness measurement for the diagnosis of breast cancer from magnetic resonance imaging examinations. Acad Radiol 18(12):1577–1581CrossRefPubMed
30.
Zurück zum Zitat Baum F, Fischer U, Vosshenrich R et al (2002) Classification of hypervascularized lesions in CE MR imaging of the breast. Eur Radiol 12(5):1087–1092CrossRefPubMed Baum F, Fischer U, Vosshenrich R et al (2002) Classification of hypervascularized lesions in CE MR imaging of the breast. Eur Radiol 12(5):1087–1092CrossRefPubMed
31.
Zurück zum Zitat Kinkel K, Helbich TH, Esserman LJ et al (2000) Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol 175(1):35–43CrossRefPubMed Kinkel K, Helbich TH, Esserman LJ et al (2000) Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol 175(1):35–43CrossRefPubMed
32.
Zurück zum Zitat El Khouli RH, Macura KJ, Jacobs MA et al (2009) Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment. AJR Am J Roentgenol 193(4):295–300CrossRef El Khouli RH, Macura KJ, Jacobs MA et al (2009) Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment. AJR Am J Roentgenol 193(4):295–300CrossRef
33.
Zurück zum Zitat Hayes C, Padhani AR, Leach MO (2002) Assessing changes in tumor vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR in Biomedicine 15(2):154–163CrossRefPubMed Hayes C, Padhani AR, Leach MO (2002) Assessing changes in tumor vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR in Biomedicine 15(2):154–163CrossRefPubMed
34.
Zurück zum Zitat Hauth EA, Jaeger H, Maderwald S et al (2006) Evaluation of quantitative parametric analysis for characterization of breast lesions in contrast-enhanced MR mammography. Eur Radiol 16(12):2834–2841CrossRefPubMed Hauth EA, Jaeger H, Maderwald S et al (2006) Evaluation of quantitative parametric analysis for characterization of breast lesions in contrast-enhanced MR mammography. Eur Radiol 16(12):2834–2841CrossRefPubMed
Metadaten
Titel
Discrimination between breast invasive ductal carcinomas and benign lesions by optimizing quantitative parameters derived from dynamic contrast-enhanced MRI using a semi-automatic method
verfasst von
Jiawen Yang
Jiandong Yin
Publikationsdatum
27.02.2019
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 7/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01421-1

Weitere Artikel der Ausgabe 7/2019

International Journal of Clinical Oncology 7/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.